E-pharmacy Company features on Shark Tank India, Program, Sony TV get legal notice for violation of Drugs and Cosmetics Act

The drugs and medicines supplied through Pharmallama without their original packaging would amount to supplying misbranded, adulterated or spurious drugs, the notice stated.

Published On 2023-03-24 10:30 GMT   |   Update On 2023-03-24 11:41 GMT
Advertisement

Bengaluru: The South Chemists and Distributors Association (SCDA) has slapped a legal notice on SONY TV, TV programme 'Shark Tank India' and E Pharmacy Company Pharmallam for violating Drug and Cosmetics Act 1940.

The legal notice has been sent to 11 parties by the Supreme Court advocate and legal consultant Shiv Verma on Wednesday.

The notice claims that all directors and shareholders of Pharmallama as well as Sony Pictures Networks India are liable for prosecution as the entire business of Pharmallama and the model adopted for it, is wholly against the Drugs and Cosmetics Act and other applicable laws.

Advertisement

The notice states that in the episode 39 of season 2 of the reality show-Shark Tank India aired by Sony Pictures Networks on February 23, the said parties had indulged in illegal act in as much as the operations of Pharmallama is in gross violation of the Drugs and Cosmetics Act, 1945 and other laws governing pharmacies and sale of drugs in India.

The drugs and medicines supplied through Pharmallama without their original packaging would amount to supplying misbranded, adulterated or spurious drugs. The Pharmallama does not own any of the licenses which are legally required for dispensing medicines by way of retail, the notice stated.

By removing medicines from its original packaging, Pharmallama essentially removes information that is mandatorily required to be disclosed to patients. The same poses substantial risk to the lives of patients as the same can result in contamination of the medicines with filth, the notice says.

Read also: CDSCO issued show cause notice to 31 firms following concerns over e-pharmacies: MoS Health Bharati Pravin Pawar

Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News